This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies.  Read our Cookies Policy.
Close
Eye News
  • Features
    • Close
    • Features
    • Allied Professions
    • Humanitarian
    • Interviews
    • AI & Oculomics
    • Ophthalmology
    • Optometry
    • Podcast videos
    • Supplements
  • Education
    • Close
    • Education
    • Learning Curve
    • Quiz
    • Top Tips
    • Trainees
    • Medico-Legal
    • The Truth Behind The Headlines
    • Case Reports
    • Pete's Bogus Journey
  • Reviews
    • Close
    • Reviews
    • Book Reviews
    • Journal Reviews
    • What's trending?
    • Tech Reviews
    • My Top Five
    • The Culture Section
  • Events
  • News
  • Product Guide
  • Industry News
  • Contact us
    • Close
    • Contact us
    • Write for Eye News
  • Home
  • Reviews
  • Journal Reviews
  • A survey of neuro-ophthalmologists on use of corticosteroids in giant cell arteritis

A survey of neuro-ophthalmologists on use of corticosteroids in giant cell arteritis
Reviewed by Claire Howard

1 December 2021 | Claire Howard | EYE - Neuro-ophthalmology | Giant Cell Arteritis, corticosteroid, dosage, vasculitis, vision Loss
Share This

While corticosteroids are the mainstay of treatment in giant cell arteritis (GCA), the type, dose, route and duration of treatment remains controversial. The authors surveyed 180 neuro-ophthalmologists on their use of this treatment via email in a two-month period. Results showed that, for patients with acute visual loss, 52% would use intravenous (IV), 46% would use IV or oral and 2% would use oral corticosteroids. In terms of dosage, 73% would use 500 to 1000mg IV methylprednisolone. For patients without acute visual loss, 67% would use the oral route, 30% IV or oral and 3% IV route of treatment. In this group, 75% would use 1.0 to 1.5mg/kg oral prednisolone. In summary, the survey results suggest a majority consensus for route and dose and confirm conventional recommendations for high dose IV corticosteroids for GCA with visual loss and lower dose oral regimes for GCA without visual loss.

 

Corticosteroid usage in giant cell arteritis.
Kanakamedala A, Hussain M, Kini A, et al.
NEURO-OPHTHALMOLOGY
2021;45(1):17-22.
Share This
CONTRIBUTOR
Claire Howard

Salford Royal NHS Foundation Trust, Salford, UK.

View Full Profile
Specialty
  • EYE - Cataract
  • EYE - Cornea
  • EYE - General
  • EYE - Glaucoma
  • EYE - Neuro-ophthalmology
  • EYE - Oculoplastic
  • EYE - Oncology
  • EYE - Orbit
  • EYE - Paediatrics
  • EYE - Pathology
  • EYE - Refractive
  • EYE - Strabismus
  • EYE - Vitreo-Retinal
Archive
  • 2025
  • 2024
  • 2023
  • 2022
  • 2021
  • 2020
  • 2019
  • 2018
  • 2017
  • 2016
  • 2015
  • 2014
  • 2013

Top Of Page

9 Gayfield Square, 
Edinburgh EH1 3NT, UK.

Call: +44 (0)131 557 4184
www.pinpoint-scotland.com

WEBSITE DETAILS
  • Cookie Policy
  • Data Protection Notice
  • Privacy Policy
  • Terms and Conditions
ABOUT US
  • Who we are
  • Register
  • Contact us
  • Contributors
  • Company Awards
DIGITAL ISSUES/GUIDELINES
  • Digital issues - Library
  • Supplements - Library
  • Guidelines
Accreditations
IPSO_FLAG_TEAL 2025.png cpdcertified.png

Pinpoint Scotland Ltd (Registered in Scotland No. SC068684) | © 2025 - Website by Gecko Agency